CD33 and neoplasm: 225Ac‐lintuzumab delivers the 225Ac payload, a high energy, short path length, alpha emitting radionuclide directly to CD33‐positive myeloid tumor cells creating lethal double‐strand breaks in DNA and leading to selective tumor cell killing.17